Drugs / GS-6212
last change Mar 2024 re-read 2 minutes ago

GS-6212

Developed for
HIV infectious disease
Investigated by
Gilead Sciences

Trials 1 · a red edge is where a trial was stopped

2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05585307 Oct 2022 → Feb 2024 HIV infectious disease Gilead Sciences Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GS-6212 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05585307
Route Oral “Administered orally” NCT05585307